Bolt Biotherapeutics (BOLT) Net Equity Issued and Repurchased (2020 - 2026)

Bolt Biotherapeutics has reported Net Equity Issued and Repurchased for 7 years, with the latest figure at $6000.0 in Q1 2026.

• Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $6000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $25000.0 (down 81.48% YoY) and the FY2025 annual result came in at $19000.0, down 82.41% from the prior year.
• Net Equity Issued and Repurchased grew to $6000.0 in Q1 2026 per BOLT's latest filing, from $5000.0 in the prior quarter.
• Over five years, Net Equity Issued and Repurchased peaked at $252000.0 in Q2 2022 and troughed at $5000.0 in Q4 2025.
• A 5-year average of $82875.0 and a median of $67500.0 in 2023 frame the typical range for Net Equity Issued and Repurchased.
• The widest YoY moves for Net Equity Issued and Repurchased: up 100.28% in 2022, down 99.51% in 2022.
• Over 5 years, Net Equity Issued and Repurchased stood at $144000.0 in 2022, then declined by 26.39% to $106000.0 in 2023, then sank by 72.64% to $29000.0 in 2024, then tumbled by 82.76% to $5000.0 in 2025, then rose by 20.0% to $6000.0 in 2026.
• According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $6000.0, $5000.0, and $14000.0 for Q1 2026, Q4 2025, and Q2 2025 respectively.